Despite the control of the COVID-19 pandemic, it remains one of the main concerns of healthcare systems throughout the world. Inflammation and hyper-reactive immune system play an essential role in developing SARS-CoV-2 infection, particularly in immunocompromised patients. Infliximab, an anti-TNFα antibody that is used in autoimmune disorders, may exert an important role in alleviating inflammation and hyper-reactive immunity. In this systematic review and meta-analysis, we have concluded that Infliximab can significantly decrease the mortality rate in patients with COVID-19. Conversely, it did not have a significant effect on the rate of hospitalization, mechanical ventilation, and adverse events during SARS-CoV-2 infection. More studies on the influence of Infliximab on patients with COVID-19 are warranted.